Abstract: Despite strong support for the provision of memory assessment services (MASs) in England and other countries, their effectiveness in improving patient outcomes is uncertain. We aimed to describe change in patients' health-related quality of life (HRQL) 6 months after referral to MASs and to examine associations with patient characteristics and use of postdiagnostic interventions. Data from 883 patients referred to 69 MASs and their informal caregivers (n = 569) were collected at referral and 6 months later. Multivariable linear regression was used to examine associations of change in HRQL (DEMQOL, DEMQOL-Proxy) with patient characteristics (age, sex, ethnicity, socioeconomic deprivation, and comorbidity) and use of postdiagnostic interventions (antidementia medications and nonpharmacological therapies). Mean HRQL improved, irrespective of diagnosis: selfreported HRQL increased 3.4 points (95% CI, 2.7-4.1) and proxyreported HRQL 1.3 points (95% CI, 0.5-2.1). HRQL change was not associated with any of the patient characteristics studied. Patients with dementia (54%) receiving antidementia drugs reported greater improvement in their HRQL but those using nonpharmacological therapies reported less improvement compared with those note receiving therapy. HRQL improved in the first 6 months after referral to MASs. Research is needed to determine longer term sustainability of the benefits and the costeffectiveness of MASs.
O ver the past decade, there has been a significant increase in the provision of memory assessment services (MASs) in England and in other countries. 1 MASs, frequently referred to as memory clinics, are ambulatory clinics that provide an integrated multiprofessional approach. 2 Their activities include: diagnostic assessment of new referrals, provision of postdiagnostic support (both pharmacological and nonpharmacological), and followup. [3] [4] [5] [6] By 2014, it was estimated that approximately £125 million a year was spent on MASs in England. 1 Despite strong support for their introduction, it has been recognized that the effectiveness of MASs in improving patient outcomes is uncertain. 7 In a recent review of the evidence, Banerjee 8 concluded that there is a "lack of studies that have evaluated the absolute and relative impact of different models of diagnostic services or the impact of diagnosis and stage of illness at diagnosis." This partly reflects the methodological challenges of evaluating a complex intervention that not only includes a wide range of diagnostic and therapeutic components but also one in which the components vary between MASs. Research has therefore either focused on single components, 9,10 on a single MAS, 11 or have focused on patients' experiences and satisfaction. [12] [13] [14] [15] [16] The aims of this study were to describe the change in health-related quality of life (HRQL) over the first 6 months after first referral to MAS; to assess whether patient characteristics, including diagnosis, are associated with changes in HRQL; and to determine whether use of antidementia drugs and nonpharmacological postdiagnostic therapies are associated with improved HRQL among those patients diagnosed with dementia.
METHODS Sampling
Initially, 80 MASs were randomly selected from 212 clinics identified by the Royal College of Psychiatrists in their national survey. 1 The survey is thought to have identified virtually all services in the country, through a review of existing registers, Internet searches, and direct contact with NHS Trusts and key individuals from each Trust (clinical audit leads, chief executives, and medical directors). Subsequently 2 MASs did not participate, 5 recruited <6 patients each and were excluded, and 4 sites did not take part in follow-up data collection at 6 months, leaving 69 MASs retained at 6-month follow-up. 17 The selected services were representative of all MASs in England based on data from the national survey: number of new referrals per month (63 vs. 72 nationally), mean waiting time for first appointment (5.8 vs. 5.2 wk), and accredited by the Royal College of Psychiatrists (26% vs. 30%). 1 Patients referred for a first appointment between September 2014 and April 2015 and their informal caregivers (if present) were eligible for inclusion in the study, provided they had enough English language to understand the consent process and complete the questionnaires. Each site recruited consecutive referrals until 25 patients were included (maximum number of 25 patients per site chosen based on the sample size requirements). Details have been reported elsewhere. 17 
Data Collection Procedures
Questionnaires were completed by patients (interviewer administered) and their informal caregiver (selfadministered) at the time of first referral and 6 months later. Data on patients' sociodemographic characteristics were collected at baseline, including: age (categorized as <75 y, 75 to 79 y, 80 to 84 y, Z85 y), ethnicity (white or other) and socioeconomic status (quintiles of the national ranking of Index of Multiple Deprivation scores based on patients' residential postcodes). 18 The patient questionnaire included disease-specific (DEMQOL 19 ) and generic (EQ-5D-3L 20 ) HRQL instruments. DEMQOL is a 28-item instrument developed for the UK population. Each item is scored on a 4-point scale, with a higher score indicating better HRQL. We used a scoring algorithm based on modern psychometric methods (Rasch Measurement Theory) to generate scores. 21 For analysis, the scores derived using this algorithm (referred to as equated scores) were linearly transformed to range from 0 to 100. The EQ-5D-3L has 5 items, each covering 1 domain: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each item has 3 levels of response. A summary EQ-5D-3L index score was calculated using value sets derived from a UK general population survey to weight and combine responses. 22 A score of 0 represents death and 1 represents perfect health, with scores <0 permitted.
Informal caregivers completed a proxy-reported disease-specific instrument of the patient's HRQL (DEM-QOL-Proxy) and also a proxy-reported generic HRQL instrument (EQ-5D-3L proxy). DEMQOL-Proxy has 31 items with responses on the same 4-point scale as DEM-QOL; equated scores were derived using the revised scoring algorithm described above. 21 EQ-5D-3L proxy has the same items as self-reported EQ-5D-3L and is scored in the same way. Carers also completed questions on the patient's use of health and social care services in the past month.
Interviewers extracted data from the patient's record on whether the patient had any prespecified comorbid conditions (heart disease, high blood pressure, problems caused by stroke, leg pain due to poor circulation, lung disease, diabetes, kidney disease, diseases of the nervous system, liver disease, cancer within the last 5 y, depression, or arthritis, based on an existing instrument 23 ). The number of comorbidities was categorized as 0, 1, 2, and Z3. In addition, data on cognitive function at baseline were extracted from the records and used to derive a 3-category cognitive function variable based on tertiles of Mini-Mental State Examination (MMSE) score 24 : category 1 (lowest function) equivalent to MMSE score <24, category 2 MMSE score 24 to 27, and category 3 (highest function) MMSE score Z28. The tertile cutoffs were also justified on the basis of established cutoffs supportive of a diagnosis of dementia at a score of <24. 25 In addition, at 6-month follow-up interviewers extracted information on the patient's diagnosis, if one had been made, and informal caregivers provided information on the antidementia medications the patient had taken during the preceding 4 weeks and receipt of any nonpharmacological therapies, such as cognitive behavior therapy, music and/or dance therapy, animal-assisted therapies, social engagement groups, walking groups, life story work, peer support groups, befriending services, memory cafes, and reminiscence therapy. At 6 months most interviews (96%) were conducted in the participant's home, with a small minority conducted at the MAS.
Statistical Analysis w
2 tests were used to compare baseline characteristics of respondents at 6 months with those of nonrespondents. Patient characteristics were summarized as means and SDs or percentages. Change in each measure of HRQL was assessed using paired t tests to compare mean scores at baseline and 6 months. Changes in HRQL among patients with and without a diagnosis and by diagnostic category (dementia, mild cognitive impairment (MCI), other, none) were compared using t tests for difference in means and linear regression.
Multivariable linear regression was used to examine the relationships between patient characteristics and change in HRQL (DEMQOL and DEMQOL-Proxy) at 6 months, with adjustment for patient characteristics (age, sex, ethnicity, socioeconomic status, comorbidities, diagnosis) and HRQL score at baseline to estimate adjusted differences in HRQL change. Clustering of patients within MASs was taken into account by using robust (clustered) SEs. Linear regression was also used to assess the relationships between postdiagnostic service use (antidementia drugs and nonpharmacological therapies) and change in HRQL in patients diagnosed with dementia, adjusting for patient characteristics, cognitive function, and HRQL at baseline, and each other (nonpharmacological therapies in the case of antidementia drugs and vice versa). Because of clustering of the use of nonpharmacological interventions in only around half of all sites, we adjusted for clinic as a random effect. Results of linear regression models are presented as adjusted differences in HRQL change score with 95% CIs (with Bonferroni adjustment for multiple testing; family-wise error rate of 0.05 per model divided by the number of tests).
To assess the effects of early or late follow-up on outcomes, sensitivity analyses were conducted excluding data from 166 participants followed up at <5 or >9 months after baseline, or with unknown date of follow-up.
All analyses were conducted using Stata V.14 (StataCorp, College Station, TX).
Ethical Approval
The study protocol was approved by the National Research Ethics Service Committee London (reference: 14/ LO/1146) and the London School of Hygiene & Tropical Medicine ethics committee (reference: 8418).
RESULTS

Recruitment and Response
Participants recruited into the study at baseline were slightly younger and had a higher proportion of men when compared with referrals who did not take part in the study, but there was no significant difference in socioeconomic status. 17 Comparison with cognitive function data from 8 clinics for all new referrals over the study recruitment period (n = 617 patients) also indicated that patients with lowest cognitive function were slightly underrepresented in our sample.
Of the 1318 patients eligible for follow-up at 6 months (944 of whom had carers also recruited), 883 (67%) patients and 569 (60%) carers completed questionnaires at 6 months and formed the main analysis sample in this study (flow chart showing sample sizes is presented in Supplemental  Fig. 1 , Supplemental Digital Content 1, http://links.lww. com/WAD/A156). Of these, 306 patients with a diagnosis of dementia and data on use of postdiagnostic interventions were included in subgroup analyses of patients with dementia.
The mean duration of follow-up was 6.5 months (SD 0.8; 98% between 5 and 9 mo). Respondents at 6 months were similar to nonrespondents for most characteristics measured at baseline [age, sex, ethnicity, comorbidities, selfreported HRQL (DEMQOL and EQ-5D), proxy-reported HRQL (EQ-5D Proxy), and whether or not they were accompanied by a carer who consented into the study]. However, respondents were less likely to be from the most deprived areas (14% vs. 21%, P < 0.001), less likely to have low cognitive function (MMSE score <24) (39% vs. 50%, P = 0.003), and had higher DEMQOL-Proxy scores (44.2 vs. 41.8, P = 0.004). Less than 7% of data were missing for all variables except cognitive function (20% missing). Cognitive function data were more likely to be missing among those with no comorbidity (31% vs. 18% missing, P = 0.001) and those who were not using nonpharmacological therapies (21% vs. 11% missing, P = 0.021), but was not associated with any other patient characteristics including diagnosis and HRQL at baseline or 6 months (DEMQOL and DEMQOL-Proxy scores). Patients with a proxy in the study were more likely to be male (53% vs. 40%, P < 0.001) and to have a diagnosis of dementia (58% vs. 42%, P < 0.001) compared with those without a participating carer, but there was no difference in age, ethnicity, SES, comorbidity, or cognitive function.
Patient Characteristics
The sociodemographic characteristics of patients are described in Table 1 . Six months after the initial referral to the MAS, 83% had received a diagnosis. About half had been diagnosed with dementia, a quarter with MCI, and 5% with various other diagnoses (including depression, alcohol-related diagnosis, cerebrovascular diseases, syndromic conditions, and other psychiatric diagnoses).
Of those with dementia, 245 (55%) had Alzheimer disease, 104 (24%) mixed or unspecified dementia, 73 (17%) vascular dementia, 8 (2%) dementia with Lewy bodies, 8 (2%) Parkinson disease, and 3 (1%) frontotemporal dementia.
Use of Postdiagnosis Interventions
Of 306 patients diagnosed with dementia and with data on use of postdiagnostic interventions, 186 (61%) were being treated with antidementia medications: donepezil (65%), memantine (19%), rivastigmine (11%), galantamine (2%), and unspecified (3%). Patients with a diagnosis of Alzheimer disease were most likely to be taking antidementia drugs (77%), whereas the lowest proportion of use was among those diagnosed with vascular dementia (14%) (P < 0.001). Use of antidementia drugs was higher among patients without comorbidities (72%) than those with comorbid conditions (58%) (P = 0.04). Of the patients who were not diagnosed with dementia (and had data on use of postdiagnostic interventions, n = 218), 12 (6%) had been prescribed an antidementia drug: 1% (n = 1) of those with MCI, 24% (n = 5) of those with other diagnosis, and 8% (n = 6) of those with no diagnosis.
Only 67 (22%) patients with dementia were using nonpharmacological interventions. Of these, 37 (55%) were also using antidementia drugs. Most (73%) patients using nonpharmacological interventions received 1 type of therapy or service, 21% received 2, and 6% received Z3. The most frequent were social engagement groups (used by 10%), memory cafes (4%), cognitive behavior therapy (3%), and befriending services (3%). These interventions were also being used by 27 people (12%) who had not been diagnosed with dementia.
Change in HRQL
Patients on average reported their HRQL had improved between baseline and 6 months: mean DEMQOL score increased 3.4 points (95% CI, 2.7-4.1), equivalent to an effect size of 0.28 SD; EQ-5D score rose 0.02 (effect size: 0.07 SD). Carers also reported patient HRQL had improved, according to DEMQOL-Proxy, though by a smaller amount (1.3 points; effect size: 0.14 SD) ( Table 2) . The pattern of improvement in self-reported HRQL (DEMQOL) was similar for those diagnosed with dementia, with MCI or with no diagnosis. For self-reported EQ-5D, improvement was only seen for those with a diagnosis of dementia. For proxy-reported HRQL (DEMQOLProxy), carers reported improvement only for those with a diagnosis of dementia or no diagnosis, and did not report improvement for those with MCI.
Association Between Patient Characteristics and Change in HRQL
Overall, change in HRQL over time was not associated with any patient characteristics in unadjusted or adjusted analyses, for both self-reported (Table 3) and proxy-reported measures of HRQL (Table 4) . Similarly, cognitive function was not associated with changes in selfreported HRQL (DEMQOL score) or proxy-reported HRQL (DEMQOL-Proxy score) in adjusted analyses (Supplemental Table 1 , Supplemental Digital Content 2, http://links.lww.com/WAD/A157).
Association Between Postdiagnostic Interventions and Change in HRQL in Dementia
Among patients diagnosed with dementia, greater improvement in self-reported HRQL was associated with use of antidementia medications in unadjusted and adjusted analyses (Table 5) : the adjusted change in DEMQOL score was 3.3 points (95% CI, 1.4-5.3) greater among patients using antidementia medications (effect size: 0.27 SD). Although there was no significant effect of nonpharmacological therapies on self-reported HRQL in unadjusted analyses, after adjustment a significantly smaller improvement in DEMQOL score was observed compared with those who did not use these services: adjusted difference À2.4 points (95% CI, À4.8 to À0.003; effect size: À 0.20 SD). In both unadjusted and adjusted analyses, proxy-reported HRQL showed no significant association with either antidementia drugs or nonpharmacological therapies.
Sensitivity analyses excluding cognitive function as a covariate from the multivariable model resulted in a smaller but still positive association between use of antidementia drugs and improvement in HRQL (2.3 points, 95% CI, 0.4-4.2; effect size: 0.19), whereas the effect size for nonpharmacological interventions was unchanged.
DISCUSSION
Main Findings
Over half of patients who were referred to MASs for memory problems were diagnosed with dementia, and a further quarter were diagnosed with MCI. HRQL among patients improved in the first 6 months after referral, irrespective of diagnosis. The magnitude of change was smaller for proxy-reported measures of HRQL than self-reported measures. Improvement in HRQL measured using EQ-5D (self-reported and proxy reported) was smaller than that measured using DEMQOL and DEMQOL-Proxy, but EQ-5D has been shown to have poor construct validity for dementia, and condition-specific measures such as DEM-QOL are recommended. 26 Change in HRQL was not associated with any patient characteristics.
Among patients who were diagnosed with dementia, 61% were being treated with antidementia drugs and 22% were treated using nonpharmacological therapies. Antidementia drugs were associated with a greater improvement in self-reported HRQL, whereas use of nonpharmacological therapies was associated with a smaller improvement. Change in proxy-reported HRQL did not show any association with use of pharmacological or nonpharmacological interventions. In adjusted analyses, cognitive function at baseline was not associated with improvement in HRQL.
Strengths and Limitations
This is the largest published study of longitudinal change in HRQL among people referred to MASs. The sample is largely representative of MASs across the whole country and the patients attending them. 17 However, the study has 4 main limitations that impact on the interpretation of the findings. First, it is not possible to attribute the observed improvement in HRQL to MASs (diagnosis and postdiagnosis support), as we do not have comparable information on those people who were not referred. Because of the lack of clinical equipoise concerning early assessment and treatment for dementia, a control arm was not considered to be ethical. Second, only two thirds of participants were followed up at 6 months. Respondents at 6 months' follow-up were more likely than nonrespondents to be more affluent and have better baseline cognitive function and proxy-reported HRQL. This may have led to overestimation of the improvement in selfreported HRQL as higher cognitive function was associated with greater improvement in unadjusted analyses. Third, data on cognitive function were missing for a fifth of participants. However, the proportion of missing values was not associated with most patient characteristics, with the exception of the number of comorbidities and use of nonpharmacological interventions. Sensitivity analyses excluding cognitive function as a covariate from the multivariable model did not change the conclusions of our analyses. Fourth, data on the use of postdiagnostic interventions (pharmacological and nonpharmacological) were not available for patients without a carer participating in the study. As these patients were more likely to be female, women diagnosed with dementia are likely to be underrepresented in our analysis of postdiagnostic interventions.
Comparisons With Other Studies
A previous study found that referral to a MAS improved HRQL at 6 months, but the study was confined to 1 service so its generalizability is uncertain. 11 On the basis of their findings, Banerjee and Wittenberg 27 modeled the likely cost-effectiveness of memory services, which suggested a gain of 0.01 to 0.02 QALYs per person-year would render the service cost-effective. This is the approximate level of improvement reported over the first 6 months by patients and their carers in this study (based on EQ-5D index), suggesting referral to a MAS may be cost-effective. However, caution is required due to the study limitations described above, and the cost-effectiveness model only considered the benefit of preventing (delaying) admission to residential care and did not include direct costs of diagnostic investigations and postdiagnosis interventions.
The absence of an association with cognitive function at baseline could suggest that improvement in HRQL is feasible in any stage from mild to moderate dementia. However, patients with lower cognitive function at baseline were less likely to be followed up at 6 months, and it is possible that patients with the greatest deterioration in cognitive function are not represented in this sample.
The level of use of antidementia drugs in those diagnosed with dementia (61%) is higher than that reported from general practice (35%). 28 However, the latter includes both recently diagnosed patients and people with longstanding dementia in whom treatment may no longer be appropriate. There have been no studies of the frequency of uptake of nonpharmacological postdiagnosis therapies with which our findings can be compared. 29 The association between antidementia drug use and HRQL found in this study may be partly due to confounding by indications (or contraindications) for these medications; however, for those who are prescribed drugs, there seems to be a greater improvement in HRQL.
In experimental studies some nonpharmacological interventions have been shown to be effective in improving Positive change score indicates improvement in HRQL. *Adjusted for clustering by clinic. wAdjusted for age, sex, ethnicity, deprivation, number of comorbidities, cognitive function, HRQL at baseline, and clinic as a random effect (in addition, medications adjusted for nonpharmacological therapies and vice versa).
Coefficients in bold P < 0.05. CI indicates confidence interval; HRQL, health-related quality of life.
HRQL and other outcomes. [29] [30] [31] There are several possible reasons for the lack of observed benefit of nonpharmacological interventions in our study, which relate to the interventions (heterogeneity of interventions included; the fidelity with which they were provided may not have been as high as in trials; duration of treatment too short for an effect to be apparent) and the patients (lack of compliance; inappropriate expectations of benefit leading to disappointment). There is also the possibility of a reverse causality effect, with patients who have experienced poorer HRQL following diagnosis potentially being more likely to be referred for such interventions. Although our findings point to a potential role of both drugs and nonpharmacological interventions in affecting patients' HRQL, more work is needed to understand the processes underlying changes in HRQL and the other factors that may explain these changes. We are currently undertaking work to explore the associations between service-level factors and HRQL, which may lead to the identification of potential mediators of change and contribute to our understanding of the mechanisms involved.
Implications
Assuming the observed improvement in HRQL reflects the benefits of what can be achieved in normal clinical practice in MASs (rather than the natural history of HRQL in dementia without any intervention), then this study provides evidence of the value of the current policy in many countries to encourage detection and intervention for people with memory problems. Further evidence regarding the underlying mechanisms of change and the sustainability of the benefits beyond 6 months is needed. The sample in this study is currently being followed up after 12 months with plans for a further extension to 5 years being drawn up.
